Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (439) 439
life sciences & biomedicine (427) 427
pd1 (285) 285
immunotherapy (275) 275
oncology (244) 244
humans (231) 231
anti-pd1 (156) 156
immunology (129) 129
cancer (124) 124
melanoma (122) 122
female (105) 105
animals (83) 83
male (79) 79
tumors (77) 77
nivolumab (73) 73
lymphocytes (72) 72
middle aged (70) 70
metastasis (68) 68
immune checkpoint (66) 66
pd-l1 (65) 65
programmed cell death 1 receptor - antagonists & inhibitors (64) 64
pdl1 (62) 62
aged (61) 61
t cells (61) 61
care and treatment (60) 60
chemotherapy (59) 59
pembrolizumab (58) 58
apoptosis (55) 55
programmed cell death 1 receptor - immunology (52) 52
adult (50) 50
lymphocytes t (49) 49
lung cancer (48) 48
immunotherapy - methods (46) 46
patients (46) 46
review (45) 45
antibodies, monoclonal - therapeutic use (43) 43
antigens (42) 42
antineoplastic agents - therapeutic use (42) 42
ctla4 (42) 42
immune checkpoint inhibitors (42) 42
ipilimumab (42) 42
cancer therapies (41) 41
cytotoxicity (40) 40
neoplasms. tumors. oncology. including cancer and carcinogens (40) 40
anti-ctla4 (39) 39
mice (39) 39
prognosis (37) 37
clinical trials (36) 36
analysis (35) 35
antibodies (35) 35
biomarkers (35) 35
research (35) 35
ligands (34) 34
biochemistry & molecular biology (33) 33
cell death (33) 33
medicine, research & experimental (33) 33
neoplasms - immunology (33) 33
programmed cell death 1 receptor - metabolism (33) 33
research & experimental medicine (33) 33
metastases (32) 32
treatment outcome (32) 32
gene expression (30) 30
health aspects (30) 30
melanoma - drug therapy (30) 30
original research (30) 30
b7-h1 antigen - antagonists & inhibitors (29) 29
drug therapy (29) 29
antineoplastic agents, immunological - therapeutic use (28) 28
cell biology (28) 28
b7-h1 antigen - metabolism (27) 27
hematology (27) 27
immune system (27) 27
medical prognosis (27) 27
mutation (27) 27
pharmacology & pharmacy (27) 27
b7-h1 antigen - immunology (26) 26
medicine & public health (26) 26
aged, 80 and over (25) 25
immune response (25) 25
medical research (25) 25
melanoma - pathology (25) 25
ctla-4 (24) 24
cytokines (24) 24
monoclonal antibodies (24) 24
breast cancer (23) 23
dermatology (23) 23
lymphoma (23) 23
melanoma - immunology (23) 23
molecular targeted therapy (22) 22
usage (22) 22
antibodies, monoclonal, humanized - therapeutic use (21) 21
clinical trials as topic (21) 21
life sciences (21) 21
lung cancer, non-small cell (21) 21
lung neoplasms - drug therapy (21) 21
survival (21) 21
t-lymphocytes - immunology (21) 21
cancer immunotherapy (20) 20
cd8 antigen (20) 20
development and progression (20) 20
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (596) 596
French (20) 20
Chinese (10) 10
Japanese (10) 10
Russian (4) 4
Spanish (4) 4
German (3) 3
Korean (2) 2
Czech (1) 1
Hungarian (1) 1
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis
by Passiglia, Francesco and Bronte, Giuseppe and Bazan, Viviana and Natoli, Clara and Rizzo, Sergio and Galvano, Antonio and Listì, Angela and Cicero, Giuseppe and Rolfo, Christian and Santini, Daniele and Russo, Antonio
Oncotarget, ISSN 1949-2553, 04/2016, Volume 7, Issue 15, pp. 19738 - 19747
PD-L1 | NSCLC | Anti-PD1/PD-L1 MoAbs | Immunotherapy | Predictive biomarker | Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Immunohistochemistry | Outcome Assessment (Health Care) - methods | Lung Neoplasms - drug therapy | Prognosis | Humans | Lung Neoplasms - metabolism | Carcinoma, Non-Small-Cell Lung - metabolism | Antineoplastic Agents | Antibodies, Monoclonal - therapeutic use | B7-H1 Antigen - immunology | Outcome Assessment (Health Care) - statistics & numerical data | B7-H1 Antigen - biosynthesis | Carcinoma, Non-Small-Cell Lung - drug therapy | Odds Ratio | Biomarkers, Tumor - biosynthesis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text The use of immunotherapy in the treatment of melanoma Ahmed Tarhini; Timothy Burns; Rahul Parikh; Guarvel Goel; Annie im
by Achkar, Tala and Tarhini, Ahmad A
Journal of hematology and oncology, 04/2017, Volume 10, Issue 1
Anti-PD1 | Anti-CTLA4 | Immunotherapy | Melanoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Inflammation‐Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti‐PD1 Antibody
by Wang, Chao and Sun, Wujin and Wright, Grace and Wang, Andrew Z and Gu, Zhen
Advanced materials (Weinheim), ISSN 0935-9648, 10/2016, Volume 28, Issue 40, pp. 8912 - 8920
anti‐PD1 | nanobiotechnology | CpG | drug delivery | cancer immunotherapy | anti-PD1 | Materials Science | Materials Science, Multidisciplinary | Physics, Condensed Matter | Science & Technology - Other Topics | Chemistry, Physical | Physics | Science & Technology | Physics, Applied | Physical Sciences | Chemistry | Nanoscience & Nanotechnology | Technology | Chemistry, Multidisciplinary | Neoplasms - therapy | Animals | Adjuvants, Immunologic | Immunotherapy | Antibodies | CpG Islands | Inflammation | Mice | Programmed Cell Death 1 Receptor - immunology | Drugs | Viral antibodies | Care and treatment | Drug delivery systems | Drug therapy | Cancer | Vehicles | Index Medicus | Immune systems | Inflammatory response | Nanostructure | Survival | Controlled release
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer
by Wöckel, Achim and Lux, Michael P and Janni, Wolfgang and Hartkopf, Andreas D and Nabieva, Naiba and Taran, Florin-Andrei and Overkamp, Friedrich and Hadji, Peyman and Tesch, Hans and Ettl, Johannes and Lüftner, Diana and Müller, Volkmar and Welslau, Manfred and Belleville, Erik and Brucker, Sara Y and Schütz, Florian and Fasching, Peter A and Fehm, Tanja N and Schneeweiss, Andreas and Kolberg, Hans-Christian
Geburtshilfe und Frauenheilkunde, ISSN 0016-5751, 11/2018, Volume 78, Issue 11, pp. 1110 - 1118
GebFra Science | Prevention | Studies | Treatment | CDK4/6 | PD1/PDL1 | Risk | Breast cancer | Metastases | Life Sciences & Biomedicine | Obstetrics & Gynecology | Science & Technology | PDL1, Studien | treatment | Prävention | PDL1, studies | Metastasen | breast cancer | metastases | 6, PD1 | CDK4 | Mammakarzinom | risk | Behandlung | Risiko | prevention
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Construction of plasmids expressing recombinant B cell epitopes of PD1
by Meilany, Sofy and Andrijono, Andrijono and Halim, Pauline Phoebe and Bela, Budiman
Health science journal of Indonesia, ISSN 2087-7021, 07/2019, Volume 10, Issue 1, pp. 1 - 7
cancer | pd1 | epitope | immunotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Can radiation-recall predict long lasting response to immune checkpoint inhibitors?
by Deutsch, Eric and Besse, Benjamin and Le Pavec, Jérôme and Le Péchoux, Cécile and Botticella, Angela and Ammari, Samy and Even, Caroline and Robert, Caroline and Levy, Antonin
Radiotherapy and oncology, ISSN 0167-8140, 01/2021, Volume 154, pp. 125 - 127
Anti-PD1 | Anti PD-L1 | Anti CTLA4 | Radioimmunotherapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab
by Lau, K. H. Vincent and Kumar, Aditya and Yang, Irene Hwa and Nowak, Richard J
Muscle & nerve, ISSN 0148-639X, 07/2016, Volume 54, Issue 1, pp. 157 - 161
myasthenia gravis | pembrolizumab | melanoma | anti‐PD1 | immune checkpoint inhibitor | autoimmune adverse effect | anti-PD1 | Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Melanoma - complications | Myasthenia Gravis - complications | Antineoplastic Agents - adverse effects | Humans | Melanoma - drug therapy | Male | Aged | Myasthenia Gravis - chemically induced | Monoclonal antibodies | Care and treatment | Myasthenia gravis | Immunotherapy | Melanoma | Skin cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune‐Checkpoint Inhibitors for Cancer Treatment
by Patel, Nisha Subhash and Oury, Anais and Daniels, Gregory A and Bazhenova, Lyudmila and Patel, Sandip Pravin
The oncologist (Dayton, Ohio), ISSN 1083-7159, 10/2018, Volume 23, Issue 10, pp. 1236 - 1241
Anti‐CTLA 4 | Pembrolizumab | Ipilimumab | Nivolumab | Anti‐PD1 | Thyroid | Anti-CTLA 4 | Anti-PD1 | Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus | Endocrinology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma
by Chan, Matthew M. K and Kefford, Richard F and Carlino, Matteo and Clements, Arthur and Manolios, Nicholas
Journal of immunotherapy (1997), ISSN 1524-9557, 11/2014, Volume 38, Issue 1, pp. 37 - 39
Arthritis | Anti-PD1 antibody | PD1 | Immunotherapy | Melanoma | Oncology | Immunology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Antibodies, Monoclonal, Humanized - adverse effects | Arthritis - chemically induced | Antineoplastic Agents - adverse effects | Humans | Melanoma - drug therapy | Middle Aged | Female | Male | Aged | Tenosynovitis - chemically induced | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Myopathie inflammatoire oculo-bulbaire et respiratoire après traitement par pembrolizumab
by Chanson, Jean-Baptiste and Rego, Cécilia Alves Do and Lenormand, Cédric and Kremer, Laurent and Lannes, Béatrice and Echaniz-Laguna, Andoni
Revue neurologique, ISSN 0035-3787, 04/2018, Volume 174, pp. S42 - S42
Traitement anticancéreux | Myopathie | Anti-PD1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Prise en charge des méningites aseptiques induites par les nouveaux traitements immunostimulants anticancéreux
by Mazoyer, Julie and Cuzzubbo, Stefania and Ursu, Renata and Belin, Catherine and Carpentier, Antoine
Revue neurologique, ISSN 0035-3787, 04/2018, Volume 174, pp. S57 - S58
Anti-CTLA4 | Méningite | Anti-PD1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text PD1 signal transduction pathways in T cells
by Arasanz, Hugo and Gato-Cañas, Maria and Zuazo, Miren and Ibañez-Vea, Maria and Breckpot, Karine and Kochan, Grazyna and Escors, David
Oncotarget, ISSN 1949-2553, 02/2017, Volume 8, Issue 31, pp. 51936 - 51945
PD-L1 | B7-H1 | PD1 | PDL1 | Cancer | Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Immunotherapy in Lung Cancer: A New Age in Cancer Treatment
by Corrales, Luis and Scilla, Katherine and Caglevic, Christian and Miller, Ken and Oliveira, Julio and Rolfo, Christian
12/2018, Advances in Experimental Medicine and Biology, ISBN 3030025047, Volume 995
Pembrolizumab | NSCLC | Precision oncology | Immunotherapy | PD-L1 and PD1 | Nivolumab | Immunotoxicity | Atezolizumab
Book Chapter
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
by Koshkin, Vadim S and Barata, Pedro C and Zhang, Tian and George, Daniel J and Atkins, Michael B and Kelly, William J and Vogelzang, Nicholas J and Pal, Sumanta K and Hsu, JoAnn and Appleman, Leonard J and Ornstein, Moshe C and Gilligan, Timothy and Grivas, Petros and Garcia, Jorge A and Rini, Brian I
Journal for immunotherapy of cancer, ISSN 2051-1426, 01/2018, Volume 6, Issue 1, pp. 9 - 9
Checkpoint inhibitor | MRCC | Non-clear cell renal cell carcinoma | Immunotherapy | Nivolumab | PD1/PDL1 pathway | Oncology | Immunology | Life Sciences & Biomedicine | Science & Technology | Complications and side effects | Development and progression | Care and treatment | Carcinoma, Renal cell | Metastasis | Index Medicus | mRCC
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Using phage-assisted continuous evolution (PACE) to evolve human PD1
by Ye, Xiaoxiao and Tu, Min and Piao, Mingxin and Yang, Liang and Zhou, Zeng and Li, Zhaopeng and Lin, Meiyu and Yang, Zhenming and Zuo, Zecheng
Experimental cell research, ISSN 0014-4827, 11/2020, Volume 396, Issue 1, pp. 112244 - 112244
PD1 | PDL1 | PACE | Interaction | Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights